Sugi Predict

Sugi Predict / Compounds / SCHEMBL574174

SCHEMBL574174

SCHEMBL574174

CSc1ncc(C=O)c(NC2CCCC2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ GABBR2 O75899 1/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51
▸ GABBR1 Q9UBS5 1/20 0.51
▸ MERTK Q12866 1/20 0.44
▸ CSNK2B P67870 1/20 0.40
▸ JAK2 O60674 6/20 0.38
▸ JAK3 P52333 1/20 0.38
▸ ADORA1 P30542 1/20 0.38
▸ ULK1 O75385 1/20 0.37
▸ JAK1 P23458 4/20 0.36
▸ SYK P43405 4/20 0.36
▸ CCNA2 P20248 1/20 0.36
▸ CDK2 P24941 1/20 0.36
▸ PPARG P37231 1/20 0.36
▸ HPGDS O60760 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4712427 0.99 KMT2A (0.50) KMT2AMEN1GABBR2CYP1A2CYP2C9
SCHEMBL2559554 0.99 KMT2A (0.50) KMT2AMEN1GABBR2CYP1A2CYP2C9
SCHEMBL2553480 0.99 KMT2A (0.49) KMT2AMEN1GABBR2CYP1A2CYP2C9
SCHEMBL3535605 0.94 MERTK (0.48) KMT2AMEN1GABBR2CYP1A2CYP2C9
SCHEMBL29507782 0.89 MERTK (0.45) KMT2AMEN1GABBR2CYP1A2CYP2C9
SCHEMBL22860490 0.89 MERTK (0.45) KMT2AMEN1GABBR2CYP1A2CYP2C9
SCHEMBL4154549 0.88 MERTK (0.41) KMT2AMEN1GABBR2CYP1A2CYP2C9
SCHEMBL16416502 0.88 MERTK (0.41) KMT2AMEN1GABBR2CYP1A2CYP2C9
SCHEMBL19857398 0.87 MAPK8 (0.45) KMT2AMEN1GABBR2CYP1A2CYP2C9
SCHEMBL30597066 0.87 MERTK (0.41) KMT2AMEN1GABBR2CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4572755-A2 CDK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-06-25 — — EP disclosed
US-20250114461-A1 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-04-10 — — US disclosed
CN-115702155-B Novel pyrido [2,3-d ] pyrimidin-7 (8H) -one derivatives 微境生物医药科技(上海)有限公司 2025-01-24 — — CN disclosed
US-20250018049-A1 COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY NIKANG THERAPEUTICS, INC. 2025-01-16 — — US disclosed
EP-4472967-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-12-11 — — EP disclosed
CN-118973581-A IRAK degradation agent and application thereof 凯麦拉医疗公司 2024-11-15 — — CN disclosed
CN-114394966-B Pyridopyrimidinone CDK2/4/6 inhibitors 辉瑞公司 2024-10-11 — — CN disclosed
US-12097261-B2 CDK2 degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-09-24 — — US disclosed
WO-2024173646-A1 CYCLIN-DEPENDENT KINASE DEGRADING COMPOUNDS INNOVO THERAPEUTICS, INC. (US) 2024-08-22 — — WO disclosed
US-20240173419-A1 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-05-30 — — US disclosed
US-20030149001-A1 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones BARVIAN MARK (US) 2003-08-07 — — US disclosed
WO-2003062246-A1 2-THIA-1,6,8-TRIAZA-NAPHTALENE-2,2-DIOXIDES AS CDK INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2003-07-31 — — WO disclosed
WO-2003062236-A1 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES WARNER-LAMBERT COMPANY LLC (US) 2003-07-31 — — WO disclosed
EP-1268476-A1 5-ALKYLPYRIDO[2,3-D]PYRIMIDINES TYROSINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2003-01-02 — — EP disclosed
US-6498163-B1 POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES AND GROWTH FACTOR MEDIATED KINASES; CANCER, RESTENOSIS, ATHEROSCLEROSIS WARNER-LAMBERT COMPANY 2002-12-24 — — US disclosed
EP-1255755-A1 PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE WARNER-LAMBERT COMPANY (US) 2002-11-13 — — EP disclosed
WO-2001070741-A1 5-ALKYLPYRIDO[2,3-D]PYRIMIDINES TYROSINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-09-27 — — WO disclosed
WO-2001055148-A1 PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE WARNER-LAMBERT COMPANY (US) 2001-08-02 — — WO disclosed
EP-0964864-A2 PYRIDO 2,3-D] PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION WARNER-LAMBERT COMPANY (US) 1999-12-22 — — EP disclosed
WO-1998033798-A2 PYRIDO[2,3-D]PYRIMIDINES AND 4-AMINO-PYRIMIDINES AS INHIBITORS OF CELL PROLIFERATION WARNER LAMBERT COMPANY (US) 1998-08-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149001-A1 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones CDK4, CDK2, CDK1 KMT2A 753/4885MEN1 2406/4885GABBR2 4374/4885
US-12097261-B2 CDK2 degraders and uses thereof CDK2, CDK20, CDK1 KMT2A 290/4885MEN1 2032/4885GABBR2 4190/4885
US-20250114461-A1 CDK2 DEGRADERS AND USES THEREOF CDK2, CDK20, CDK1 KMT2A 290/4885MEN1 2032/4885GABBR2 4190/4885
US-20250018049-A1 COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY CDK2, SKP2, CDK5 KMT2A 1513/4885MEN1 2817/4885GABBR2 4567/4885
US-20240173419-A1 CDK2 DEGRADERS AND USES THEREOF CDK2, CDK20, CDK1 KMT2A 290/4885MEN1 2032/4885GABBR2 4190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.